NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said it has closed its acquisition of Blackhawk Biosystems, a privately held maker of quality-control products for infectious disease testing.
Bio-Rad CEO Norman Schwartz said he expects this acquisition will help his company expand its online quality control and inter-laboratory peer group comparison.
Financial terms of the acquisition were not disclosed.
In the past year Bio-Rad also purchased ProteOptics and made an agreement to acquire Ciphergen’s proteomic tools business, including the company’s SELDI platform.
For more on Bio-Rad’s corporate strategy, including its acquisition outlook, read this interview with Bio-Rad vice president Brad Crutchfield conducted by GenomeWeb News sister publication ProteoMonitor.